This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Jump to content

About this module


Dr Richard Russell and Prof Christian Taube discuss data from clinical trials presented at ATS 2016. Watch this video to understand key results and reanalyses from the most important clinical trials investigating combination therapy in COPD presented at ATS 2016. Data from clinical trials suggests that combination therapies are more effective than monotherapies. Data also suggests that LAMA/LABA reduces the risk of exacerbations more than LABA/ICS. Overall, data shows patients with COPD benefit from optimal combination therapy regardless of disease severity and baseline symptom levels.

This webinar episode is part of the ATS 2016 webinar series outlined below.


Webinar series

  1. Introduction to the ATS 2016 webinar series for COPD
  2. Asthma-COPD overlap syndrome (ACOS)
  3. Phenotypes, traits and clusters in COPD
  4. Eosinophils and other biomarkers for COPD
  5. Combination therapy in COPD: recent data from clinical trials
  6. ICS use in COPD
  7. Exacerbations in COPD
  8. Co-morbidities of COPD
  9. Structural mechanisms of COPD and the lung microbiome
  10. Biomass fuels and their role in COPD
  11. Smoking cessation and e-Cigarettes
  12. Pulmonary rehabilitation for COPD
  13. Diagnosis and spirometry in COPD
Module Duration
5 mins
Created Date
Monday, August 1, 2016
Dr Richard Russell and Prof Christian Taube
Content Type
Developments in Respiratory, Treatment approaches